Abstract
To evaluate the long-term safety and efficacy of a simplified basal-bolus regimen of once-daily insulin degludec/insulin aspart (IDegAsp) with additional IAsp vs. a standard basal-bolus insulin regimen of insulin detemir (IDet) with IAsp in adults with Type 1 diabetes. This was an open-label trial comprising a 26-week core phase followed by a 26-week extension phase. Participants were randomized to IDegAsp once daily at the main meal and IAsp at remaining meals (IDegAsp+IAsp), or IDet (once or twice daily) and IAsp at all meals (IDet+IAsp). Insulins were titrated to target plasma glucose of < 5 mmol/l (< 90 mg/dl) at pre-breakfast (IDegAsp and IDet) and at pre-meal (IAsp). After 52 weeks, the overall confirmed hypoglycaemia rate was 31.8 episodes/patient-years of exposure (PYE) with IDegAsp+Asp and 36.7 episodes/PYE with IDet+IAsp, and the rate of nocturnal confirmed hypoglycaemia was significantly lower with IDegAsp+Asp than with IDet+IAsp (3.1 vs. 5.4 episodes/PYE, respectively; P < 0.05). Adverse event rates were comparable between groups. Mean HbA1c decreased from baseline by 0.7% (IDegAsp+IAsp) and 0.6% (IDet+IAsp), achieving 60 or 61 mmol/mol (7.6% or 7.7%, respectively), at Week 52. The mean total daily insulin dose was ...Continue Reading
References
Jun 21, 2005·Journal of General Internal Medicine·Sandeep VijanTimothy P Hofer
Mar 30, 2007·Diabetes, Obesity & Metabolism·K Hermansen, M Davies
Jan 28, 2010·Diabetes Care·Mark PeyrotLuther B Travis
Jul 21, 2010·Expert Opinion on Pharmacotherapy·Michael Gejl JensenJørgen Rungby
Feb 3, 2011·Diabetes Care·Tim HeiseRolf Jorde
Mar 1, 2012·Diabetes Care·Eda CengizStuart A Weinzimer
Apr 10, 2012·Pharmaceutical Research·Ib JonassenUlla Ribel
Apr 24, 2012·Lancet·Simon HellerUNKNOWN BEGIN Basal-Bolus Type 1 Trial Investigators
May 19, 2012·Diabetes, Obesity & Metabolism·T HeiseH Haahr
Jul 24, 2012·Drugs·Andreas LieblViswanathan Mohan
Aug 31, 2012·Diabetes Care·Irl B HirschMelanie Davies
Jan 29, 2013·Diabetes, Obesity & Metabolism·M BrodD M Bushnell
Apr 6, 2013·Diabetes, Obesity & Metabolism·Y OnishiS Nakamura
May 29, 2013·Diabetic Medicine : a Journal of the British Diabetic Association·B W BodeUNKNOWN BEGIN® Basal-Bolus Type 1 trial investigators
Jun 14, 2013·The Journal of Clinical Endocrinology and Metabolism·Ruth S WeinstockUNKNOWN T1D Exchange Clinic Network
Apr 8, 2014·Diabetes, Obesity & Metabolism·M J DaviesUNKNOWN BEGIN BB T1 Study Group
May 9, 2014·Diabetes Care·Gregory R FulcherLeo K Niskanen
Citations
Oct 12, 2017·Expert Opinion on Biological Therapy·Takahisa HiroseMads Peter Hemmingsen
Dec 16, 2018·Diabetes, Obesity & Metabolism·Rebecca S HolmesMarian S McDonagh
Nov 2, 2019·Current Drug Targets·Ping WuHao Fang
Aug 14, 2018·The Cochrane Database of Systematic Reviews·Ruth MartisJulie Brown
Jun 24, 2020·Current Medicine Research and Practice·Meda VenkatasubbaiahSuggala V Satyanarayana
Jul 4, 2020·Diabetes, Obesity & Metabolism·Roopa MehtaGregory Fulcher
Jan 17, 2017·Diabetic Medicine : a Journal of the British Diabetic Association·R I G Holt
Jan 7, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Andrej JanežLea Smircic-Duvnjak
Oct 4, 2016·Clinical Pharmacokinetics·Hanne HaahrTim Heise
Dec 19, 2016·Drugs·Suzanne M de la Monte
Jul 8, 2016·International Journal of Clinical Practice·A KumarJ S Christiansen
May 26, 2018·Advances in Therapy·Sanjay KalraA G Unnikrishnan
Apr 22, 2017·Nature Reviews. Endocrinology·Chantal MathieuKatrien Benhalima
Mar 5, 2021·The Cochrane Database of Systematic Reviews·Bianca HemmingsenBernd Richter
Mar 30, 2021·Frontiers in Endocrinology·Tevfik DemirDilek Gogas Yavuz
Jul 29, 2021·Naunyn-Schmiedeberg's Archives of Pharmacology· MartinYu-Shi Tian
Dec 2, 2021·The Journal of Clinical Endocrinology and Metabolism·Mark A JarosinskiMichael A Weiss